摘要
肿瘤患者中肌肉减少症的患病率超过40%。肿瘤化疗患者罹患肌肉减少症的风险高于一般人群,且肿瘤患者发生肌肉减少症后更容易出现化疗不良反应,导致生存质量低下和预后不良。肌肉减少症的发生涉及激素变化、炎性反应等,其分子机制涉及调控肌肉蛋白合成和降解的分子通路。维生素D通过作用于Fox-O亚族和泛素-蛋白酶体通路改善肌肉减少症,而ω-3脂肪酸通过增强mTOR核糖体活性而增强肌肉合成代谢,二者均可对化疗产生正向影响。虽然目前关于维生素D和ω-3脂肪酸用于肿瘤化疗患者肌肉减少症预防和治疗的研究数据相对缺乏,但其应用前景值得期待。
The incidence rate of sarcopenia in cancer patients is up to 40%.Tumor chemotherapy patients have a higher risk of sarcopenia than the general population,and tumor patients are more likely to have adverse reactions to chemotherapy after sarcopenia,leading to reduced quality of life and poor prognosis.The occurrence of sarcopenia involves hormonal changes and inflammatory responses,and its molecular mechanism involves molecular pathways that regulate muscle protein synthesis and degradation.Vitamin D improves sarcopenia by acting on Fox-O subfamily and ubiquitin-proteasome pathway.Omega-3 fatty acids play a role in muscle anabolic via upregulation mTOR signalling in promoting ribosome biogenesis.However,both vitamin D and omega-3 fatty acids have a positive effect on chemotherapy.Although the current research data on vitamin D and omega-3 fatty acids for the prevention and treatment of sarcopenia in tumor chemotherapy patients is relatively lacking,their application prospects are worth looking forward to.
作者
蔡丽雅
赵文芝
杨振鹏
贺源
邓丽
张艳
石汉平
CAI Li-ya;ZHAO Wen-zhi;YANG Zhen-peng;HE Yuan;DENG Li;ZHANG Yan;SHI Han-ping(Department of Clinical Nutrition,Affiliated Beijing Shijitan Hospital,Capital Medical University,Beijing 100038,China)
出处
《中国医学前沿杂志（电子版）》
2020年第1期13-19,共7页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
基金
国家重点研发计划(2017YFC1309200)。
